
Opinion|Videos|May 26, 2025
Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.
Advertisement
Episodes in this series

Lorlatinib’s Unique Adverse Event Profile
Key Themes:
- Cognitive effects, hypercholesterolemia, and peripheral neuropathy with lorlatinib
- Impact of adverse events on treatment selection
- Monitoring and management of cholesterol levels
Notable Insights:
- Dr Dietrich discussed lorlatinib’s unique adverse event profile and its impact on treatment decisions
Dr Lovly outlined best practices for monitoring and managing lorlatinib-induced hypercholesterolemia
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
3
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
4
Making the Genetic Models Match the Ancestry of Patient Populations
5













































